SkyePharma licensed rights to Shire Pharmaceuticals to manufacture, distribute and market SkyePharma’s Solaraze (diclofenac) for actinic keratosis in Australia, New Zealand, South Africa and other Pacific Rim countries. The deal could worth up to £2.3 M.